Pyxis Oncology, Inc. (PYXS)

Pyxis Oncology Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	16.15	-	-	-	-
Cost of Revenue	0.48	-	-	-	-
Gross Profit	15.67	-	-	-	-
Selling, General & Admin	22.49	30.83	37.35	18.66	3.85
Research & Development	58.75	49.59	86.13	51.05	9.05
Operating Expenses	81.24	80.42	123.48	69.72	12.89
Operating Income	-65.57	-80.42	-123.48	-69.72	-12.89
Interest & Investment Income	7.04	6.63	2.76	0.02	0.07
Earnings From Equity Investments	-	-	-	-0.23	-
Other Non Operating Income (Expenses)	-	-	-	-6.05	-
EBT Excluding Unusual Items	-58.53	-73.79	-120.72	-75.98	-12.83
Pretax Income	-79.5	-73.79	-120.72	-75.98	-12.83
Income Tax Expense	-2.16	-	-	-	-
Net Income	-77.33	-73.79	-120.72	-75.98	-12.83
Net Income to Common	-77.33	-73.79	-120.72	-75.98	-12.83
Shares Outstanding (Basic)	58	40	33	8	1
Shares Outstanding (Diluted)	58	40	33	8	1
Shares Change (YoY)	46.46%	20.80%	288.93%	724.14%	53.41%
EPS (Basic)	-1.32	-1.85	-3.65	-8.95	-12.45
EPS (Diluted)	-1.32	-1.85	-3.65	-8.95	-12.45
Free Cash Flow	-57.91	-77.44	-95.73	-35.87	-11.57
Free Cash Flow Per Share	-0.99	-1.94	-2.90	-4.22	-11.22
Gross Margin	97.06%	-	-	-	-
Operating Margin	-406.11%	-	-	-	-
Profit Margin	-478.95%	-	-	-	-
Free Cash Flow Margin	-358.66%	-	-	-	-
EBITDA	-62.59	-78.49	-122.77	-69.07	-12.43
D&A For EBITDA	2.98	1.93	0.71	0.65	0.47
EBIT	-65.57	-80.42	-123.48	-69.72	-12.89
Revenue as Reported	16.15	-	-	-	-

Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q